chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On Thursday April 1, 10 days after the vaccine (1st shot)  I began to experience itch hives all over my body.  I took Benadryl at 2 pm and 8 pm to relieve the symptoms. It helped. At 7 am,  morning of Friday April 2,  I took Claritin to relieve symptoms but it was not effective. At 9:15 am,  morning of Friday April 2,  my lips and cheeks began to go numb, and it felt as if my throat and tongue were swelling.  At 9:30 am. I checked in to the ER.  They monitored my condition and indicated my blood pressure and oxygen levels were normal. At approximately 10:15 am, my mouth began to feel normal again. While at the ER, the  doctor checked out my hives and gave me Prednisone. She also gave me a prescription for 4 days of Prednisone, 50 mg tablets,  and advised to continue taking Benadryl to relieve symptoms. I have taken Prednisone once a day for past couple days and Benadryl 3 times a day. Hives are still present today Sunday April 4, 2021 but milder than previous days.[Not certain if this is important, but on  day 3 and 4 after the vaccine, I reported dizziness on mobile app check-in. The dizziness went away by day 5. I had no other symptoms appear until day 10 reported here.
MASSIVE SHINGLES OUTBREAK; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the subject experienced massive shingles outbreak. The action taken with covid-19 vaccine  was not applicable. The outcome of massive shingles outbreak was not reported. This report was non-serious. This case, from the same reporter is linked to 20210526416 and 20210526445.; Sender's Comments: V0-Medical assessment comment not required as per standard operating procedures, as the case was assessed as non-serious.
also had wheezing  and would get short of breath after just short walks; also had wheezing  and would get short of breath after just short walks; Had congestion at time of vaccination; not much coughing but "spuduim" was yellowish but never solid green; Not much energy; This is a spontaneous report from a contactable consumer (patient). A 64-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection; Batch/Lot number and Expiration Date: not reported) via an unspecified route of administration, administered in left arm on 21Mar2021 at 16:00 (at the age of 64 years old) as dose 1, single for COVID-19 immunisation at a Pharmacy or Drug Store. The patient has no medical history, has no known allergies and prior to vaccination was not diagnosed with COVID-19. Concomitant medication included thyroid (ARMOUR THYROID) taken for an unspecified indication, start and stop date were not reported. The patient had no other vaccine in four weeks. On 22Mar2021, the patient had congestion at time of vaccination but no fever, not much coughing but "spuduim" (as reported) was yellowish but never solid green and had not much energy. However congestion got worse every day. So on 26Mar2021, the patient went to emergency room/department or urgent care as the patient also had wheezing and would get short of breath after just short walks. On 04Apr2021, the patient started feeling better but was still coughing and still not much energy. Treatment was given in response to the events which included 6 pack antibiotics, albuterol inhaler and 3 days of steroids. Since vaccination, the patient has not been tested for COVID-19. Outcome of all events was recovering.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
my health significant damage. My health feel the evening of the second shot; There were no warnings for anyone on genetic therapy not to take it./It was not safe./ There were no warnings as to the contents nor interaction with other drugs; There were no warnings for anyone on genetic therapy not to take it./It was not safe./ There were no warnings as to the contents nor interaction with other drugs; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID:  The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for Covid-19 immunization.  The following information was reported: GENERAL PHYSICAL HEALTH DETERIORATION (non-serious), outcome "unknown", described as "my health significant damage. My health feel the evening of the second shot"; DRUG-GENETIC INTERACTION (non-serious), DRUG INTERACTION (non-serious), outcome "unknown" and all described as "There were no warnings for anyone on genetic therapy not to take it./It was not safe./ There were no warnings as to the contents nor interaction with other drugs".  Additional information: The patient reported that Pfizer vaccine had caused patient health significant damage. Patient health feel the evening of the second shot. There were no warnings for anyone on genetic therapy not to take it. Patient was advised by the doctor that it was safe. It was not safe. There were no warnings as to the contents nor interaction with other drugs. This activity is tantamount to genocide and you are directly responsible.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
patient has a sore arm for 3 weeks and her daughter was saying care taker nurse found a lump at the site of injection and they are taking her to the primary care this friday on 03/18/2022.
Liver enzymes elevated after 2nd dose; Liver enzymes elevated after 2nd dose; received 2nd dose on 12/14/2022; This non-serious case was reported by a consumer via call center representative and described the occurrence of elevated liver enzymes in a 65-year-old female patient who received HBV (Engerix B adult) for prophylaxis.   The patient's past medical history included elevated liver enzymes (history of unexplained, elevated liver enzymes). Concomitant products included HEPATITIS B VACCINE (ENGERIX B ADULT).   On 14-DEC-2022, the patient received the 2nd dose of Engerix B adult. On 14-DEC-2022, an unknown time after receiving Engerix B adult, the patient experienced drug dose administration interval too long (Verbatim: received 2nd dose on 12/14/2022). On an unknown date, the patient experienced elevated liver enzymes (Verbatim: Liver enzymes elevated after 2nd dose) and condition aggravated (Verbatim: Liver enzymes elevated after 2nd dose). The outcome of the elevated liver enzymes was not recovered/not resolved and the outcome of the condition aggravated was not reported and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the elevated liver enzymes and condition aggravated to be related to Engerix B adult.     It was unknown if the company considered the elevated liver enzymes and condition aggravated to be related to Engerix B adult.   Additional Information: GSK Receipt date: 13-Mar-2023 and 14-Mar-2023 The reporter was the patient. The patient had history of unexplained, elevated liver enzymes, but noticed they were even more elevated after receiving first and second dose of Engerix B.  The patient had liver function test prior to receiving first dose of Engerix B showed an AST level of 25 and ALT level of 29.  The patient reported AST level was 54 and ALT level was 140 when liver function test completed after first and second dose of Engerix B. The reporter consented to follow up.
Rash mostly on back and abdomen, some on whole body. Prescribed Diphenhydramine
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received vaccine after the 12 hours of expiry) in a 19-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034F21A) for COVID-19 vaccination. No Medical History information was reported.    On 30-Nov-2021 at 8:30 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received vaccine after the 12 hours of expiry). On 30-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Patient received vaccine after the 12 hours of expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant information was not reported. Treatment information was not reported.
Got a fever of 101.7.  Took Ibuprofen, 1 every 4 hours, 3x.  Sweated it out overnight.  Fine on Sunday, 3/21/21
Headache, Fever- 102.3, Severe Body aches, Severe chills, couldn't feel botoms of feet, metallic taste in mouth, hives, tiredness, stuffy nose, confusion, delerium.
This spontaneous report was received from a nurse refers to an unspecified number of patients of unknown age and gender. No concurrent condition or medical history was reported. On an unknown date the patient was vaccinated with VARIVAX (Merck), (0.5 ml, subcutaneous). No concomitant therapy was reported. It was reported that improperly stored VARIVAX (Merck) doses had been administered (Incorrect Product Storage). No adverse effects was reported. The outcome of the event was unknown. No product quality issue was reported. Additional information has been requested.
Patient went to Dr's office 03/27/14 reporting headache, nausea and fever of 101F.Called 08/27/14 temp decreased feeing better.
Severe vomiting, nervousness, nausea, taken to Emergency Room by wife and treated.
pt recv vax;devel flu like sx characterized by fever,malaise,deep body/muscle aches,HA & n;
patient describes "after almost one week after vaccine I experienced tenderness in my arm, difficulty lifting, and can rotate shoulder, but cannot reach backward to lift pants."
Had a virus; Missed appointment for second dose of Covid Vaccine; This is a spontaneous report from a non-contactable consumer (patient). This consumer reported similar events for 2 patients (himself and wife). This is the 1st of 2 reports.   This male patient of an unspecified age received the 1st dose of (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, on 29Mar2021, as single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient had a virus on an unspecified date with outcome of unknown and missed appointment for second dose Covid Vaccine on 19Apr2021. The reporter stated they were told they will be rescheduled.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) :Same reporter/event/drug, different patients
Information has been received from a physician concerning a 66 year old female whose husband vaccinated with zoster vaccine live (Oka/Merck). Concomitant therapy included alendronate sodium (MSD). On approximately 10-AUG-2007 the patient experienced four or five itchy pimples. This is one of several reports from the same source. Additional information has been requested.
Pt with large round 8cm x 7cm warm to touch indurated & tender area (red with ecchymosis) treated with AUGMENTIN x 10 days.
1010- shot given. 1020- coughing, followed by wheezing.   1025- 25ml benadryl/5mgxyzal 1037 0.3ml epi 1043- 60mg prednisone 1050-0.3ml epi 1115-0.3ml epi 1143- O2 sasts to 92% 1159- 0.3ml epi. to ED- recemic epi, glucagon, IV fluids.  admitted overnight for observation.
This spontaneous report as received from a nurse refers to a 6months 10 days old female patient. No concurrent condition, medical history or allergy/drug reaction were reported. On an unspecified date, the patient was vaccinated with improperly stored (exposed to 52.8 Fahrenheit for a total of 105 hours) ROTATEQ lot # K016313, exp. date: 31-MAY-2016 and lot # K011663, exp. date 20 MAY-2016 (dose and strength unspecified). No concomitant medications were reported. No adverse experiences have been reported so far. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports received from the same reporter. Additional information is not expected, no conctact details were provided.
Pt. received shots, stated she was "fine".  Pt. told to sit in the blue chairs while mom checked out.  Mom stated "she just went limp."  Taken by w/c to back and laid down, legs moved & juice given.
This spontaneous report was received from a register nurse, concerning a 2 months-old female patient. The patient's concurrent conditions, concomitant medications, drug reactions or allergies were not reported. The patient had history of spitting up. On an unspecified date, the patient was vaccinated with ROTATEQ (lot #, expiration date, strength and dose were not reported), administered orally for prophylaxis. It was reported that the patient spit up 30 to 40 minutes after receiving the ROTATEQ (Infantile spitting up). No treatment was given for the event. The outcome of the infantile spitting up was not provided. The relatedness between the infantile spitting up and the ROTATEQ was not reported. No product quality complaint (PQC) was involved. Additional information has been requested.
This spontaneous report as received from a nurse refers to a 2 month old female patient. Pertinent medical history, concomitant medication, drug reactions and allergies were not provided. On 24-APR-2014, the patient inadvertently received a partial dose of ROTATEQ oral (dose, frequency, lot number and expiration date were not reported) due to vomiting during administration of the dose. The outcome of events was unknown. The relatedness between vomiting and ROTATEQ was not reported. Additional information has been requested.
Acute chest pain 2 days after vaccination which failed to respond analgesics. No reports of syncope, palpitations. Diagnosed with myocarditis by EKG and enzymes along with MRI.
Difficulty breathing; This case was reported by a consumer via interactive digital media and described the occurrence of difficulty breathing in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 30th August 2022, the patient received the 2nd dose of Shingles vaccine. In August 2022, less than a week after receiving Shingles vaccine, the patient experienced difficulty breathing. On an unknown date, the outcome of the difficulty breathing was not recovered/not resolved.   It was unknown if the reporter considered the difficulty breathing to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 31-AUG-2022 Reporter's Comment: This case was reported by the patient via interactive digital media. The patient received second dose of shingles shot yesterday (the day before reporting) and experienced difficulty breathing. Additional Supportive Information: The follow-up would not possible as no contact details were available.
Within minutes, she had fatigue, increased injection site soreness. Redness, muscle pain, swelling noted within 10 minutes after TRUMENBA injection.
fever; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 28 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 08May2021 17:00 (Lot number: EW0168, Expiration Date: 05Aug2021) at the age of 28 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hypothyroidism" (ongoing). Concomitant medication(s) included: LEVOTHYROXINE taken for hypothyroidism, start date: 2013 (ongoing). Vaccination history included: Bnt162b2 (Dose: 1, Time: 16:05 PM, Anatomical site of injection:  Left arm, Route of administration: Intramuscular, Batch/lot number: EW0171, Expiry date: 04Jul2021), administration date: 17Apr2021, when the patient was 28 years old, for COVID-19 immunization. The following information was reported: PYREXIA (non-serious) with onset 08May2021, outcome "unknown", described as "fever". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pyrexia.  Additional information : Treatment as Acetaminophen liquid. Prior vaccination (within 4 weeks): None.   No follow-up attempts are possible. No further information is expected.
Hospitalized with covid; fully vaccinated with booster. Expired 12/4/22.
No adverse reaction in beginning days. Slight tenderness the first day then soreness self-resolved. Day 5 itching occurred at injection site. Redness and swelling began about one to two hours after. Size was about 1.5 inches in diameter and expanded to 4 inches in diameter. Raised red bump that was warm to touch.  Right armpit began to be sore on 12/28 with a noticeable lump and two canker sores in the mouth appeared. This spot remains but is resolving by about 1/4inch daily as of 12/30. Lump in armpit resolving as well.
Given DTap instead of TD no adverse reaction, Given 3rd MMR no adverse reaction should have been given 2nd Hep A.
Base on data submitted in system and related registries. Patient received expired COVID -19 vaccine dose .
This spontaneous report as received from a nurse refers to patients of unknown age. The nurse assumed that since 03-JUL-2014, the patients received GARDASIL (lot no, route not reported). There was no concomitant medication. The nurse reported about temperature excursions, with first excursion was on 03-JUL-2014. The worst case temperature was 0 Celsius and the total time frame was 54 hours. GARDASIL was one of the affected products. Other products involved RECOMBIVAX HB, ROTATEQ, PNEUMOVAX23 (single dose) and M-M-R II. Excursion was supported. No patient concerns or effects were reported to office post administration of these vaccines. The patients did not seek medical attention. Product quality complaint was not reported. The outcome of events was unknown. This is one of several reports from the same reporter. Additional information has been requested.
Covid arm - rash traveling down from injection down arm. Itchy and painful. Had same reaction after 1st dose, but rash appeared sooner this time.
Information has been received from a registered nurse. This report refers to a patient of unspecified age and gender, who had been administered a dose of VARIVAX (Merck) on 29-MAR-2013 (lot # 671341/1250AA, expiration date reported as 11-AUG-2013) that was stored in improper temperatures. No adverse event was reported. This is one of several reports from the same source. Additional information is not expected.
One week post third vax, this pt had trouble getting up (ached), experienced the sensation of heavy limbs, could not shave (NOS), felt pain at the injection site radiating to his fingertips, and had irregular heartbeat. He was unable to do his normal activities, but was able to drive some days and his symptoms were better on some days than others. Treated with Vioxx, which was ineffective.  The most recent information received on 04/28/2000 reports that the condition of the pt is slightly improved.
This spontaneous report as received from a consumer refers to a 59 years old female patient with allergy to some antibiotics (unspecified) and no pertinent medical history. On 17-OCT-2012, the patient was vaccinated intramuscular with, 0.5 ml PNEUMOVAX23 (lot not provided). Other suspect therapies included influenza virus vaccine (unspecified) on 17-OCT-2012. Concomitant medications included simvastatin (manufacturer unknown) and ZYRTEC. The consumer stated that on 17-OCT-2012 she received PNEUMOVAX23 in her right arm and the Flu Vaccine (manufacturer unspecified) in her left as concomitantly. On 18-OCT-2012 she developed a high fever 102 F, severe chills, body aches, soreness and tenderness at the injection site. On 19-OCT-2012 her upper right arm became red, hard and painful. The patient went to the doctor on 20-OCT-2012 and was prescribed KEFLEX dosage and ADVIL. No further AE information provided. At the time of the report the patient's adverse events persisted. The relatedness for adverse events was unknown for PNEUMOVAX23. Additional information has been requested.
episodes of dizziness and "flushing' to face lasting seconds to minutes intermittently all day interfering with day to day living
This spontaneous report was received from a pharmacist, via a company representative, referring to a 65 year old male patient. The patient's medical history and concurrent condition were not reported. On 16-NOV-2014, the patient was vaccinated with a first dose of ZOSTAVAX (Lot#, expiration date and route of administration were not reported) both. No adverse experience was reported. There was no product quality complaint (PQC) involved. Additional information has been requested.
CHILLS; SORE ARM; This spontaneous report received from a patient concerned a 47 year old female. The patient's weight was 110 pounds, and height was 63 inches. The patient's concurrent conditions included seasonal allergy, abstains from alcohol, and non-smoker, and other pre-existing medical conditions included no drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  No concomitant medications were reported. On 12-APR-2021, the subject experienced sore arm. On 13-APR-2021, the subject experienced chills. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, and sore arm on 13-APR-2021. This report was non-serious.
Throwing up, waves of emotions that brought past suicidal thoughts back, chills, uncontrollable sweating, joints throbbing
Information has been received regarding a case in litigation concerning a female who on 13-MAY-1992, was vaccinated with her final dose of three dose series of Recombivax HB (manufacturer unknown).  She had a fourth dose on 03-May-1994, and alleged two other administrations in 1994 (for which she was unable to produce records).  In January 1998 at approximately 61 years old, the patient experienced vestibular dysfunction, where she had 2 attacks of vertigo.  An MRI revealed that there were lesions in her brain that were consistent with Multiple Sclerosis (M.S.), however, they were also consistent with the aging process.  A subsequent interpretation was that the MRI did not show lesions.  Her clinical condition had never reflected MS and her doctors, (although initially posting that she might have MS), backed away from that diagnosis and decided that she had vestibular dysfunction.  The patient felt that vestibular dysfunction was related to therapy with Recombivax HB, however, this was not medically supported.  The outcome was unknown.  No further information is available.
This spontaneous report was received from a registered nurse concerning a patient of currently 3 months of age and unknown gender. The patient's pertinent medical history, concomitant medication and drug allergies/reactions were not provided. On an unspecified date, the patient was vaccinated with an improperly stored doses of PEDVAXHIB lot# M047666, expiration date: 24-OCT-2019 for prophylaxis (dose, frequency, route of administration were not reported). The administered dose of the vaccine experienced a temperature excursion 32 degree Fahrenheit to 35 degree Fahrenheit for 6 hours. There were no adverse effects reported. There was no previous temperature excursion. Data logger was involved. No product quality complaint was involved. This is one of several reports received from the same reporter.